$MIST News

Milestone Pharmaceuticals: Taking The Long View

Wells Fargo Maintains Overweight on Milestone Pharmaceuticals, Lowers Price Target to $7

Milestone Pharmaceuticals May Offer Up To $100M Common Shares Via Cantor Fitzgerald Sales Agreement

Milestone Pharmaceuticals Files Prospectus To Offer Securities Up To $300M

Milestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call Transcript

Milestone Reports Q1 Results, Highlights Initial CARDAMYST Sales

Milestone Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript

Milestone Expands CARDAMYST Push Into Europe, China And New AFib Trial

Milestone Pharmaceuticals shares are trading higher after the company announced that Express Scripts has added CARDAMYST nasal spray to its commercial national formularies.

Milestone Pharmaceuticals shares are trading higher after the company announced that Express Scripts has added CARDAMYST nasal spray to its commercial national formularies.

Milestone Pharmaceuticals Announces Availability Of Nasal Spray For The Conversion Of Acute Symptomatic Episodes Of Paroxysmal Supraventricular Tachycardia Through Commercial National Formularies, Effective March 27

Milestone Pharmaceuticals Inc (MIST) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ...

Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call Transcript

Milestone Pharmaceuticals shares are trading lower. The company reported its Q4 financial results.

Milestone Pharmaceuticals Q4 Earnings Call Highlights

Milestone Pharmaceuticals (NASDAQ:MIST) Reports First Revenue with Q4 2025 Earnings, Beats Estimates

Milestone Pharmaceuticals: Q4 Earnings Snapshot

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT

Milestone Pharmaceuticals Q4 EPS $(0.16), Inline, Sales $1.546M Beat $1.200M Estimate

Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts